| 05/07/23 | 07:00:05 | 5 Jul 2023 | | Additional Agreement with Leading Biopharma | RNS |
| 27/06/23 | 07:00:04 | 27 Jun 2023 | | Arecor granted key patents in Europe and China | RNS |
| 26/06/23 | 07:00:04 | 26 Jun 2023 | | Arecor presents positive data for AT247 at ADA | RNS |
| 09/06/23 | 15:35:54 | 9 Jun 2023 | | Exercise of rollover options & Total Voting Rights | RNS |
| 09/06/23 | 12:43:31 | 9 Jun 2023 | | Result of AGM | RNS |
| 09/06/23 | 07:00:04 | 9 Jun 2023 | | AGM Statement | RNS |
| 24/05/23 | 07:00:14 | 24 May 2023 | | Director/PDMR Shareholding | RNS |
| 15/05/23 | 07:00:06 | 15 May 2023 | | TETRIS PHARMA LAUNCHES OGLUO® IN DENMARK & NORWAY | RNS |
| 04/05/23 | 16:00:01 | 4 May 2023 | | ARECOR 2022 ANNUAL REPORT AND NOTICE OF AGM | RNS |
| 26/04/23 | 07:00:09 | 26 Apr 2023 | | Arecor Granted Key U.S Patent | RNS |
| 21/04/23 | 07:00:04 | 21 Apr 2023 | | Arecor on Investor Meet Company Platform | RNS |
| 20/04/23 | 07:00:58 | 20 Apr 2023 | | Unaudited Preliminary Results for 2022 | RNS |
| 05/04/23 | 07:00:02 | 5 Apr 2023 | | Arecor Appoints Chief Business Officer | RNS |
| 22/03/23 | 07:00:02 | 22 Mar 2023 | | FIRST PATIENT DOSED IN AT278 CLINICAL TRIAL | RNS |
| 13/03/23 | 16:35:23 | 13 Mar 2023 | | Price Monitoring Extension | RNS |
| 13/03/23 | 14:05:22 | 13 Mar 2023 | | Second Price Monitoring Extn | RNS |
| 13/03/23 | 14:00:20 | 13 Mar 2023 | | Price Monitoring Extension | RNS |
| 13/03/23 | 11:05:38 | 13 Mar 2023 | | Second Price Monitoring Extn | RNS |
| 13/03/23 | 11:00:22 | 13 Mar 2023 | | Price Monitoring Extension | RNS |
| 13/03/23 | 09:05:41 | 13 Mar 2023 | | Second Price Monitoring Extn | RNS |
| 13/03/23 | 09:00:21 | 13 Mar 2023 | | Price Monitoring Extension | RNS |
| 01/03/23 | 07:00:12 | 1 Mar 2023 | | ARECOR TO PRESENT SHARESOC WEBINAR | RNS |
| 24/02/23 | 16:44:40 | 24 Feb 2023 | | Holding(s) in Company | RNS |
| 24/02/23 | 07:00:05 | 24 Feb 2023 | | Notice of Results | RNS |
| 16/02/23 | 07:00:05 | 16 Feb 2023 | | Arecor Granted Patents in India and the US | RNS |
| 14/02/23 | 07:01:01 | 14 Feb 2023 | | ARECOR STRENGTHENS COLLABORATION WITH PARTNER | RNS |
| 30/01/23 | 07:00:04 | 30 Jan 2023 | | Arecor Publishes Data for AT278 in Diabetes Care | RNS |
| 19/01/23 | 07:00:05 | 19 Jan 2023 | | BUSINESS UPDATE | RNS |
| 12/01/23 | 07:00:03 | 12 Jan 2023 | | ARECOR ANNOUNCES TRANSFER OF AT307 TO HIKMA | RNS |
| 04/01/23 | 07:00:04 | 4 Jan 2023 | | TETRIS PHARMA LAUNCHES OGLUO® IN AUSTRIA | RNS |
| 12/12/22 | 10:04:20 | 12 Dec 2022 | | TETRIS PHARMA SERVICE AGREEMENT WITH SYNEOS HEALTH | RNS |
| 06/12/22 | 16:03:14 | 6 Dec 2022 | | Grant of LTIP Options and PDMR Dealing | RNS |
| 22/11/22 | 07:00:08 | 22 Nov 2022 | | ARECOGRANTED PATENT IN JAPAN AND SOUTH KOREA | RNS |
| 22/11/22 | 07:00:08 | 22 Nov 2022 | | ARECOR TO COMMENCE SECOND TRIAL WITH AT278 | RNS |
| 17/11/22 | 07:00:06 | 17 Nov 2022 | | Grant of AESOP Options and PDMR Dealing | RNS |
| 10/11/22 | 07:00:06 | 10 Nov 2022 | | SPECIALTY HOSPITAL FORMULATION COLLABORATION | RNS |
| 08/11/22 | 07:00:06 | 8 Nov 2022 | | Exercise of options and PDMR dealing | RNS |
| 01/11/22 | 07:00:06 | 1 Nov 2022 | | TETRIS PHARMA LAUNCHES OGLUO® IN GERMANY | RNS |
| 11/10/22 | 07:00:16 | 11 Oct 2022 | | Headline results from Phase I trial of AT247 | RNS |
| 20/09/22 | 11:03:16 | 20 Sept 2022 | | Arecor Presents Positive Data for AT278 at EASD | RNS |
| 08/09/22 | 07:00:11 | 8 Sept 2022 | | Interim Results for six months ended 30 June 2022 | RNS |
| 17/08/22 | 07:00:08 | 17 Aug 2022 | | Notice of Interim Results | RNS |
| 09/08/22 | 07:00:04 | 9 Aug 2022 | | ARECOR GRANTED EUROPEAN PATENTS | RNS |
| 05/08/22 | 15:33:04 | 5 Aug 2022 | | Holding(s) in Company | RNS |
| 05/08/22 | 11:52:33 | 5 Aug 2022 | | Holding(s) in Company | RNS |
| 04/08/22 | 14:09:35 | 4 Aug 2022 | | Holding(s) in Company | RNS |
| 04/08/22 | 14:08:55 | 4 Aug 2022 | | Holding(s) in Company | RNS |
| 04/08/22 | 10:45:02 | 4 Aug 2022 | | Holding(s) in Company | RNS |
| 04/08/22 | 08:55:53 | 4 Aug 2022 | | Director/PDMR Dealings | RNS |
| 02/08/22 | 16:52:04 | 2 Aug 2022 | | Arecor on Investor Meet Company Platform | RNS |
